Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MTOR | P42345 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | THPO | P40225 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740976 | 1.00 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2580815 | 1.00 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL15668655 | 0.90 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL15668653 | 0.90 | LMNA (0.59) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2585199 | 0.90 | LMNA (0.47) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL29066139 | 0.89 | LMNA (0.58) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2584809 | 0.89 | LMNA (0.58) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL15972295 | 0.87 | LMNA (0.56) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL29035988 | 0.86 | LMNA (0.55) | LMNAALDH1A1HTTMTORTP53 | |
| SCHEMBL2402321 | 0.86 | LMNA (0.55) | LMNAALDH1A1HTTMTORTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739992-A1 | DETECTION OF TARGET MOLECULES IN DRIED BIOLOGIC MATRICES | SomaLogic Operating Co., Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025064457-A1 | METHODS OF SOLID-PHASE NUCLEIC ACID HYBRIDIZATION | SOMALOGIC OPERATING CO., INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092447-A1 | Methods of Solid-Phase Nucleic Acid Hybridization | SOMALOGIC OPERATING CO., INC. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2025010324-A1 | DETECTION OF TARGET MOLECULES IN DRIED BIOLOGIC MATRICES | SOMALOGIC OPERATING CO., INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-112638845-B | Improved proteomic multiplex assays | 私募蛋白质体运营有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-105658658-B | Cytidine-5-formyl amine-modified polynucleotide composition and its correlation technique | 私募蛋白质体公司 | 2019-11-05 | — | — | CN | disclosed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3071588-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
| CN-105658658-A | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | 私募蛋白质体公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2015077292-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | SOMALOGIC, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | LMNA 764/4885ALDH1A1 2775/4885HTT 1504/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | LMNA 764/4885ALDH1A1 2775/4885HTT 1504/4885 |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | LMNA 764/4885ALDH1A1 2775/4885HTT 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.